A rapid test for congenital syphilis screening
Ended Project Grant Awarded Last action
- Award ID
- R41HD107895
- Recipient
-
Meliolabs Inc. UEI MEHHH8HCNVB3
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,782
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date
- Place of performance
- Santa Clara, CA 95054, USA
Award details come from USAspending.gov.
Description
- Abstract
- Since 2014, congenital syphilis (CS) cases in the united states, caused by the transplacental transmission of the bacterium treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise >185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fetuses, and 4 in 10 pregnancies will end in stillbirth or infant death. Infants contracting CS may be asymptomatic, but they can also suffer from serious early- (< 3 months) and late-stage (>2 years) manifestations of multisystemic syphilis infection, including skin lesions, bone deformities, liver abnormalities, and blindness. Treponema strains are extremely difficult to culture, thus sensitive and specific diagnosis requires multi-step testing paradigms that are labor intensive, subject to false-positives and false-negatives, and limited in scalability. No single test is currently commercially available that enables accurate, rapid, inexpensive, and simple widespread testing for syphilis infection. Yet, such a test could reduce syphilis-associated stillbirth and perinatal death by up to 75%. Here we propose to extend the capabilities of "meltseq", our novel pathogen identification platform that is specifically geared towards neonatal infections and small-volume blood samples. Phase i builds upon our previous work in broad-based pathogen identification at single-genome levels to develop a fast and actionable treponema detection and strain differentiating assay. In addition, we will reduce testing times from ~3 hours to
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $299,891 | |
| Original award | $299,891 |
Quick answers
Who received award R41HD107895?
R41HD107895 was awarded to Meliolabs Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on September 19, 2022.
How much is award R41HD107895 worth?
$599,782 has been obligated on R41HD107895.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award